1. Executive Summary
1.1 Summary Points of this Report
1.2 Aims, Scope and Format of this Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. Introduction to Vaccines
2.1 Immunisation and Types of Vaccine
2.1.1 Vaccines: A Healthcare Triumph
2.1.2 The Immune System and Natural Immunity
2.1.3 Edward Jenner Laid the Foundation for Modern Vaccines
2.1.4 Vaccines Work by Creating Artificial Immunity
2.1.5 Vaccine Formulation
2.1.6 Types of Vaccine
2.1.7 Live, Attenuated Vaccines
2.1.8 Recombinant Live Vaccines
2.1.9 Inactivated Vaccines
2.1.10 Toxoid Vaccines
2.1.11 Subunit Vaccines
2.1.12 Conjugate Vaccines
2.1.13 Recombinant Subunit Vaccines
2.1.14 DNA Vaccines
2.1.15 Recombinant Vector Vaccines
2.2 Vaccine Preventable Diseases
2.2.1 Chickenpox and Shingles
2.2.2 Cholera
2.2.3 Diphtheria
2.2.4 Haemophilus Influenzae Type B (Hib) Diseases
2.2.5 Hepatitis A
2.2.6 Hepatitis B
2.2.7 Human Papillomavirus (HPV) - Cervical Cancer
2.2.8 Influenza
2.2.9 Seasonal Influenza
2.2.10 Pandemic Influenza
2.2.11 Influenza Vaccination
2.2.12 Japanese Encephalitis
2.2.13 Measles
2.2.14 Meningococcal Diseases (Neisseria Meningitidis)
2.2.15 Mumps
2.2.16 Pertussis
2.2.17 Polio
2.2.18 Rabies
2.2.19 Rotavirus Infections
2.2.20 Rubella
2.2.21 Streptococcus Pneumoniae Infections
2.2.22 Tetanus
2.2.23 Tick-Borne Encephalitis
2.2.24 Tuberculosis
2.2.25 Typhoid
2.2.26 Yellow Fever
3. The Global Vaccines Market, 2009-2025
3.1 Global Vaccines Market, 2009
3.1.1 Vaccine Types
3.1.2 Leading Vaccine Types
3.1.3 Leading Vaccine Brands
3.1.4 Leading Vaccine Manufacturers
3.2 Global Vaccine Market Forecast, 2010-2025
3.2.1 Opportunities in the Vaccines Market
3.2.2 The World Vaccine Market Will Double by 2015
3.2.3 The World Vaccine Market: Fastest- and Slowest-Growing Categories
3.3 Growth in Vaccine Market to Drive Efficiency in Vaccine Manufacturing
4. The Global Vaccines Manufacturing Market, 2009-2025
4.1 The Current State of Vaccines Manufacturing: The Supply Perspective
4.1.1 Conservative Nature: Market Slowly Opening to New Technology
4.1.2 Classification of Vaccine Manufacturers
4.1.3 Vaccine Manufacturing Market by Value, 2009: Dominated by A Few Global Manufacturers
4.1.4 Vaccine Manufacturing Market by Volume, 2009: A Contrasting Picture
4.2 Global Vaccine Production Forecast, 2010-2025
4.2.1 Vaccine Production Forecasting Method
4.2.2 Production Forecast for Vaccines, 2010-2020
4.2.3 Production Forecast for Vaccines, 2020-2025
4.3 Leading National Markets for Vaccine Manufacturing
4.3.1 Leading Vaccine Manufacturing Destinations, 2009
4.3.2 Vaccine Manufacturing: Regional Forecast, 2010-2025
4.3.3 Europe as the Manufacturing Hub of Global Vaccine Manufacturers
4.3.3.1 Vaccine Manufacturing Units of Top 10 Vaccine Manufacturers in European Countries
4.3.4 Vaccine Production in Developing Countries
4.3.4.1 Developing Countries as Leading Manufacturers for Specific Vaccine Types
4.3.4.2 Promoting Vaccine Production in Developing Countries
4.3.4.3 Factors Driving the Shift towards Developing Countries
5. Contract Manufacturing in the Global Vaccines Sector, 2009-2025
5.1 The Challenges in Outsourcing
5.2 Contract Manufacturing Market for Vaccines, 2009-2025
5.2.1 Market Size for Contract Manufacturing of Vaccines, 2009
5.2.2 Market Forecast, 2010-2025: Witnessing Growth Parallel to the Vaccines Market
5.3 Outsourced Activities
5.4 Changes in the Vaccine Market to Drive Contract Manufacturing
5.5 Prominent Contract Manufacturers with Vaccine Production Capabilities
5.5.1 SynCo Bio Partners B.V.
5.5.1.1 Overview
5.5.1.2 Facilities and Equipment
5.5.1.3 Capabilities
5.5.1.4 Focus on Vaccines
5.5.2 Baxter BioPharma Solutions
5.5.2.1 Overview
5.5.2.2 Facilities
5.5.2.3 Capabilities
5.5.2.4 Future Outlook
5.5.3 Meridian Life Science, Inc.
5.5.3.1 Overview
5.5.3.2 Facilities
5.5.3.3 Capabilities
5.5.3.4 Focus on Vaccines
5.5.3.5 Revenues
5.5.3.6 Future Outlook
6. Vaccine Manufacturing: Processes and Developments from 2010
6.1 Steps Involved in Vaccine Production
6.1.1 Egg-Based Manufacturing for Viral Vaccines: Traditional Technology
6.2 Development in Vaccine Manufacturing: Novel Technologies Reaching the Market
6.3 New Substrates for Vaccine Production
6.3.1 Egg-Based Manufacturing to Cell-Based Manufacturing Technology
6.3.2 Cell-Based Techniques have Advantages over Egg-Based Vaccine Production
6.3.3 Mammalian Cell Lines
6.3.3.1 MCDK (Madin Darby Canine Kidney Cells)
6.3.3.2 Vero Cells
6.3.3.3 Per C6 Cells
6.3.4 Avian-Derived Cell Lines
6.3.4.1 EB66 Stem Cell Technology: Vivalis
6.3.4.2 AGE1.CR: A Patent-Protected Duck Cell Line Developed by ProBioGen AG
6.3.5 Plant-Based Vaccines
6.3.5.1 Medicago's Proficia VLP Vaccine Technology
6.3.5.2 iBioLaunch Vaccine Technology: Plant-Based Production Platform from iBio
6.3.6 Insect Egg Based Production Systems
6.3.6.1 Novavax
6.3.6.2 Protein Sciences Corporation (PSC)
6.4 Next-Generation Expression Systems and Vectors: Increasing Production Yield
6.4.1 AdVac Technology: Crucell
6.4.2 AdCEV Vectors: AfriVax
6.4.3 Pfenex Expression Technology: Pfenex (A part of Dow Chemical Company before December 2009)
6.5 Increasing Use of Disposables/ Single-Use Systems
7. SWOT Analysis for Vaccines Manufacturing
7.1 Principal Strengths
7.1.1 Vaccines as Important Agents for Disease Control
7.1.2 New Vaccine Technologies
7.1.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines
7.1.2.2 New Types of Vaccine
7.1.2.3 New Adjuvants for Vaccines
7.1.2.4 New Vaccine Delivery Mechanisms and Formulations
7.1.2.5 Other Developments in Vaccine Technology
7.1.3 New High-Margin Vaccines
7.1.4 Vaccines Will Not Face Significant Generic Competition
7.1.5 Personalised Vaccines
7.2 Weakness
7.2.1 Difficult to Forecast Demand for Vaccines
7.2.2 High Costs and Complex Manufacturing Processes
7.2.3 Unknown Viral Strains
7.2.4 Limitations of the Production Facility: Difficult to Change Over to Different Product
7.3 Opportunities for Vaccine Manufacturers and Manufacturing Countries
7.3.1 China, India and Brazil Will Become Hubs for Manufacturing Paediatric Vaccines
7.3.2 Vaccines for Diseases Currently Without a Vaccine
7.3.3 Biodefence
7.3.3.1 The Future for Bioterrorism Vaccines
7.3.4 Pandemic-Preparedness
7.3.5 Changing World Demographics
7.3.5.1 Population Increase
7.3.5.2 Emerging-Market Economies
7.4 Threats
7.4.1 Consolidation Among Vaccine Manufacturers
7.4.2 Vaccines in the Developing World
7.4.2.1 Vaccine Distribution Networks
7.4.2.2 Vaccine Costs in Developing Countries
8. Expert Opinions
8.1 Mr. Patrick Lucy, Vice President, Business Development, Pfenex Inc.
8.1.1 About the Pfenex Technology
8.1.2 On Pfenex' Service Offerings
8.1.3 On Current State of Vaccine Manufacturing
8.1.4 On Novel Platforms Driving Vaccines Market
8.2 Dr Roger Lias, President & Group Commercial Director, Eden Biodesign, Inc.
8.2.1 On The Contract Manufacturing Market
8.2.2 On Future Growth Prospects of Vaccines Contract Manufacturing
8.2.3 About Eden Biodesign and its Capabilities
8.2.4 Industry Drivers
9. Conclusions
9.1 The Vaccines Market Can Experience Strong Growth from 2010 to 2025
9.2 Drivers for Change in Vaccines Manufacturing
9.3 Comparison of Vaccine Manufacturing Capabilities
9.4 Concluding Thoughts
List of Tables
Table 2.1 Vaccine-Preventable Diseases: Statistics from Recent Years
Table 2.2 Influenza Virus Types
Table 3.1 Definition of Vaccine Types Used in this Report
Table 3.2 Vaccine Sales ($bn) and Shares (%) by Type, 2009
Table 3.3 Vaccine Sales ($bn) and Shares (%) by Brand, 2009
Table 3.4 Vaccine Sales ($m) and Shares (%) by Manufacturer, 2009
Table 3.5 Global Vaccine Market Forecast ($bn), 2010-2025
Table 3.6 Global Vaccine Market Forecast by Vaccine Type ($bn), 2010-2025
Table 4.1 Global Vaccine Production (bn doses), 2009
Table 4.2 Global Vaccine Production (bn doses): Forecast, 2009-2020
Table 4.3 Global Vaccine Production (bn doses): Forecast, 2020-2025
Table 4.4 Vaccine Production (bn doses) in Leading National Sectors, 2009
Table 4.5 Vaccine Production (bn doses) in Leading European Countries, 2009
Table 4.6 Vaccine Production (bn doses): Forecast by Leading National Markets, 2009-2015
Table 4.7 Manufacturing Facilities of Top 10 Vaccine Manufacturers, 2010
Table 4.8 Manufacturing Sites of Top 10 Vaccine Manufacturers: Location and Number in Europe, 2010
Table 4.9 Prominent Emerging Vaccine Manufacturers, 2010
Table 4.10 Development of Influenza Vaccine Production in Developing Countries, 2010
Table 5.1 Vaccines Contract Manufacturing Market Revenues ($m), 2009
Table 5.2 Vaccines Contract Manufacturing Market Revenue ($m) Forecast, 2009-2015
Table 5.3 Vaccines Contract Manufacturing Market Revenue ($m) Forecast, 2016-2025
Table 5.4 Some Outsourcing Deals In the Vaccine Manufacturing Space
Table 5.5 Prominent Contract Manufacturing Organisations Offering Vaccine Manufacturing, 2010
Table 5.6 Meridian Life Science Revenue ($m), 2008 and 2009
Table 6.1 Cell-Culture Based Vaccine Manufacturing Technologies and Product Developments, 2010
Table 6.2 Commercial Licensing Deals for Vivalis' EB66 Cell Technology
Table 6.3 Licensing Deals for ProBioGen AG's AGE1.CR Cell Technology
Table 6.4 Vaccine Development Pipeline using Medicago's Proficia VLP Vaccine Technology, 2010
Table 6.5 Vaccine Development Pipeline using iBio's iBioLaunch Vaccine Technology, 2010
Table 6.6 Vaccine Development Pipeline using Protein Sciences Corporation's BEVS Vaccine Technology, 2010
Table 6.7 Vaccine Development Pipeline using Crucell's AdVac Technology, 2010
Table 6.8 Benefits and Drawbacks of using Disposable Technology for Vaccine Production, 2010
Table 6.9 Companies Providing Disposable Biomanufacturing Platforms/ Systems, 2010
Table 7.1 SWOT Analysis for the Global Vaccine Manufacturing Sector, 2010
List of Figures
Figure 3.1 Vaccine Market Shares (%) by Type, 2009
Figure 3.2 Vaccine Market Shares (%) by Brand, 2009
Figure 3.3 Vaccine Market Shares (%) by Manufacturer, 2009
Figure 3.4 Global Vaccine Market Forecast ($bn), 2010-2025
Figure 3.5 Global Vaccine Market Shares (%) by Vaccine Type, 2010
Figure 3.6 Global Vaccine Market Shares (%) by Vaccine Type, 2015
Figure 3.7 Global Vaccine Market Shares (%) by Vaccine Type, 2020
Figure 3.8 Global Vaccine Market Shares (%) by Vaccine Type, 2025
Figure 4.1 Shares (%) of Global Vaccine Production by Volume, 2009
Figure 4.2 Global Vaccine Production (bn doses): Forecast, 2009-2025
Figure 4.3 Regional Shares (%) of Global Vaccine Production, 2009
Figure 4.4 Vaccine Production Shares (%) by Leading European Countries, 2009
Figure 4.5 Regional Shares (%) of Global Vaccine Production, 2010
Figure 4.6 Regional Shares (%) of Global Vaccine Production, 2015
Figure 4.7 Regional Shares (%) of Global Vaccine Production, 2020
Figure 4.8 Regional Shares (%) of Global Vaccine Production, 2025
Figure 4.9 Regional Shares (%) of Manufacturing Facilities of Top 10 Vaccine Manufacturers, 2010
Figure 5.1 Market Shares (%) of Vaccines in Biologics Contract Manufacturing, 2009
Figure 5.2 Vaccines Contract Manufacturing Market Revenue ($m) Forecast, 2009-2025
Figure 5.3 Revenue Share (%) of Meridian Life Science in Meridian Bioscience Revenues, 2009
Figure 6.1 Steps in Vaccine Production, 2010
Figure 6.2 Egg-Based Production Process for Viral Vaccines, 2010
Figure 6.3 Influenza Vaccine Production Using Cell-Based Manufacturing Method, 2010
Figure 6.4 Novavax' Insect Egg-Based Vaccine Production Process, 2010
Figure 9.1 Comparison of Vaccine Manufacturing Capabilities of Different Organisation Types, 2010